CTRL Therapeutics, a Chicago, IL-based biotechnology company developing a cell therapy platform for solid tumors, raised $10M in Seed funding.
The round was led by General Catalyst with participation from Intermountain Health, FACIT and other investors.
The company intends to use the funds for further optimization and validation of its proprietary technology platform and expansion of its team.
Founded by Shana Kelley, CTRL Therapeutics is a biotechnology company developing a cell therapy platform that works on the challenges of existing cell therapy technologies by extracting circulating tumor reactive lymphocytes (cTRL) from blood. It builds on the benefits of tumor-infiltrating lymphocyte (TIL) therapies while providing increased efficacy by improving the immune phenotype, quality, and consistency of harvested therapeutic cells. This method can allow for wider access to the patient while avoiding invasive and costly surgery, while offering superior cost-effectiveness and simplified manufacturing.
FinSMEs
26/04/2023